WO2024028782 - NLRP3 INFLAMMASOME INHIBITORS
National phase entry is expected:
Publication Number
WO/2024/028782
Publication Date
08.02.2024
International Application No.
PCT/IB2023/057819
International Filing Date
02.08.2023
Title **
[English]
NLRP3 INFLAMMASOME INHIBITORS
[French]
INHIBITEURS DE L'INFLAMMASOME NLRP3
Applicants **
NOVARTIS AG
Inventors
GE, Xiaobin
MATTES, Henri
SHI, Zhicong
XIA, Mei
YE, Ning
Priority Data
63/370,300
03.08.2022
US
PCT/CN2023/097282
30.05.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2597 | |
| EPO | Filing, Examination, Granting | 11009 | |
| Japan | Filing, Examination, Granting | 2262 | |
| South Korea | Filing, Examination, Granting | 2154 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
23,962
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.[French]
sont tels que définis dans la description, qui inhibent l'activité de l'inflammasome de la protéine 3 du récepteur de type NOD (NLRP3). L'invention concerne en outre les procédés pour leur préparation, des compositions pharmaceutiques et des médicaments les contenant, et leur utilisation dans le traitement de maladies et de troubles médiés par NLRP3.